Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 160
interventional 151
Observational 8
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 40
Drug|Other 26
Biological|Drug 11
Biological|Drug|Other 9
Biological|Drug|Procedure|Radiation 7
Biological|Other 7
Biological 6
Drug|Other|Procedure|Radiation 6
Biological|Drug|Other|Procedure|Radiation 4
Biological|Drug|Radiation 4
Drug|Procedure|Radiation 4
Drug|Genetic|Other 3
Drug|Other|Procedure 3
Drug|Procedure 3
Biological|Drug|Other|Procedure 2
Biological|Other|Procedure 2
Other|Procedure 2
Behavioral|Other 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Procedure 1
Biological|Procedure|Radiation 1
Biological|Radiation 1
Device 1
Dietary Supplement|Other 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1
Drug|Radiation 1
Other 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 129
United States|Italy 4
United Kingdom 3
United States|Canada 3
United States|Germany|Italy 3
Canada 1
Germany 1
Italy 1
Spain 1
Tanzania 1
United States|Denmark|Germany 1
United States|Italy|Spain|United Kingdom 1
United States|Italy|United Kingdom 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 90
2 13
3 4
4 4
5 7
6 3
7 2
8 1
10 3
11 5
12 2
13 3
15 1
16 2
17 2
20 1
22 1
23 1
25 2
30 1
31 1
37 1
123 1

Phase

Phase Study_Count
Phase 2 60
Phase 1 56
Phase 1/Phase 2 16
N/A 13
Phase 3 3
Early Phase 1 2
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 110
2 24
3 9
4 1
5 1
7 1
NA 5

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 7.0 5.00000 2.00000 18.0000 12.0 206.0 650
1st Qu. 13.5 29.00000 24.00000 28.7500 34.0 287.0 650
Median 20.0 63.00000 37.00000 37.5000 53.5 368.0 650
Mean 20.0 84.92308 49.07143 46.5625 73.9 637.0 650
3rd Qu. 26.5 160.00000 60.00000 52.0000 99.0 852.5 650
Max. 33.0 210.00000 210.00000 124.0000 348.0 1337.0 650

Trial Group Type

group_type Group_Count
Experimental 187
Active Comparator 7
NA 5
No Intervention 4
Other 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 118
Parallel Assignment 26
Sequential Assignment 3
NA 2
Crossover Assignment 1
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 138
Supportive Care 10
Basic Science 2
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 2
United States|Canada 2
France 1
Italy 1
Korea, Republic of 1
Tanzania|Uganda 1

Sites per Study

Site_count Study_Count
1 3
2 1
6 1
12 1
66 1
107 1

Enrollment Metrics

Measure Observational
Min 43.000
1st Qu 136.000
Median 188.500
Mean 779.875
3rd Qu 274.500
Max 4893.000

Observation Model

observational_model Study_Count
NA 3
Case-Only 2
Case-Control 1
Case Control 1
Cohort 1

Time Perspective

time_perspective Study_Count
Retrospective 3
Cross-Sectional 2
NA 2
Prospective 1

Registries

Studies by Country

Country Study_Count
France 1

Sites per Study

Site_count Study_Count
7 1

Enrollment Metrics

Measure Registries
Min 6000
1st Qu 6000
Median 6000
Mean 6000
3rd Qu 6000
Max 6000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
9 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03314974 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders https://ClinicalTrials.gov/show/NCT03314974 Recruiting Masonic Cancer Center, University of Minnesota 2025-01-10
NCT03223610 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT03223610 Recruiting National Institutes of Health Clinical Center (CC) 2022-09-01
NCT03038672 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas https://ClinicalTrials.gov/show/NCT03038672 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT03015896 Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03015896 Recruiting Ohio State University Comprehensive Cancer Center 2020-04-30
NCT02996773 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine https://ClinicalTrials.gov/show/NCT02996773 Recruiting University of Arizona 2022-11-29
NCT02950220 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02950220 Completed Ohio State University Comprehensive Cancer Center 2018-11-19
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02797470 Recruiting AIDS Malignancy Consortium 2021-09-30
NCT02722668 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep https://ClinicalTrials.gov/show/NCT02722668 Recruiting Masonic Cancer Center, University of Minnesota 2028-05-31
NCT02669017 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) https://ClinicalTrials.gov/show/NCT02669017 Completed ADC Therapeutics S.A. 2019-02-21
NCT02661035 Allo HSCT Using RIC for Hematological Diseases https://ClinicalTrials.gov/show/NCT02661035 Recruiting Masonic Cancer Center, University of Minnesota 2023-03-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT01028716 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01028716 Recruiting Fred Hutchinson Cancer Research Center 2024-01-04
NCT01925131 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia https://ClinicalTrials.gov/show/NCT01925131 Active, not recruiting Southwest Oncology Group 2022-01-31
NCT02568553 Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02568553 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT01092182 Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01092182 Active, not recruiting National Institutes of Health Clinical Center (CC) 2021-02-28
NCT02483000 Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies https://ClinicalTrials.gov/show/NCT02483000 Active, not recruiting Fred Hutchinson Cancer Research Center 2019-11-17
NCT02481310 Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02481310 Active, not recruiting Northwestern University 2021-07-31
NCT02443831 CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies https://ClinicalTrials.gov/show/NCT02443831 Active, not recruiting University College, London 2020-10-31
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02393157 Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL https://ClinicalTrials.gov/show/NCT02393157 Recruiting New York Medical College 2020-12-31
NCT02337985 Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02337985 Active, not recruiting City of Hope Medical Center 2022-06-30
NCT02199184 Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT02199184 Recruiting M.D. Anderson Cancer Center 2022-12-31
NCT02153580 Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02153580 Recruiting City of Hope Medical Center 2021-12-31
NCT02134782 Yoga Fatigue Study https://ClinicalTrials.gov/show/NCT02134782 Recruiting The Hospital for Sick Children 2023-10-31
NCT01314014 Imexon for Relapsed Follicular and Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT01314014 Completed University of Rochester 2013-03-31
NCT01290120 Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt’s Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01290120 Completed Northern Italy Leukemia Group 2014-06-30
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT01962636 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases https://ClinicalTrials.gov/show/NCT01962636 Recruiting Masonic Cancer Center, University of Minnesota 2023-10-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01943682 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma https://ClinicalTrials.gov/show/NCT01943682 Completed Children’s Hospital Medical Center, Cincinnati 2019-03-31
NCT01897012 Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01897012 Completed National Cancer Institute (NCI) 2018-10-31
NCT01842672 Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia https://ClinicalTrials.gov/show/NCT01842672 Recruiting New York Medical College 2019-12-31
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01815749 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01815749 Active, not recruiting City of Hope Medical Center 2020-10-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01791595 A Phase I Trial of AZD3965 in Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT01791595 Active, not recruiting Cancer Research UK 2021-05-31
NCT01786135 A Safety Study of SGN-CD19A for B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01786135 Completed Seattle Genetics, Inc. 2015-08-31
NCT01786096 A Safety Study of SGN-CD19A for Leukemia and Lymphoma https://ClinicalTrials.gov/show/NCT01786096 Completed Seattle Genetics, Inc. 2017-05-30
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01722305 Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma https://ClinicalTrials.gov/show/NCT01722305 Completed Mayo Clinic 2016-06-03
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01597778 Double Cord Versus Haploidentical (BMT CTN 1101) https://ClinicalTrials.gov/show/NCT01597778 Active, not recruiting Medical College of Wisconsin 2020-06-30
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01474681 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01474681 Completed Novartis 2016-10-03
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01397825 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine https://ClinicalTrials.gov/show/NCT01397825 Completed Takeda 2015-02-05
NCT01363128 Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma https://ClinicalTrials.gov/show/NCT01363128 Completed M.D. Anderson Cancer Center 2020-01-30
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04191187 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04191187 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-12-31
NCT03833180 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03833180 Recruiting VelosBio Inc. 2021-03-31
NCT03793140 A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations https://ClinicalTrials.gov/show/NCT03793140 Recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT03677128 Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment https://ClinicalTrials.gov/show/NCT03677128 Recruiting Duke University 2021-06-30
NCT03674411 Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy https://ClinicalTrials.gov/show/NCT03674411 Recruiting Masonic Cancer Center, University of Minnesota 2023-07-31
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01184885 A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy https://ClinicalTrials.gov/show/NCT01184885 Completed Thomas Jefferson University 2011-03-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01109069 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01109069 Completed Pharmacyclics LLC. 2019-04-26
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00994500 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma https://ClinicalTrials.gov/show/NCT00994500 Completed National Cancer Institute (NCI) 2011-07-31
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00867529 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00867529 Completed Fred Hutchinson Cancer Research Center 2015-03-31
NCT00864227 Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) https://ClinicalTrials.gov/show/NCT00864227 Completed Medical College of Wisconsin 2011-04-30
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00849147 Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) https://ClinicalTrials.gov/show/NCT00849147 Completed Medical College of Wisconsin 2011-06-30
NCT00807495 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00807495 Completed Takeda 2011-01-04
NCT01859819 Treatment for Advanced B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01859819 Recruiting New York Medical College 2019-06-30
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01434472 High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01434472 Active, not recruiting Fred Hutchinson Cancer Research Center 2020-07-24
NCT03136146 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia https://ClinicalTrials.gov/show/NCT03136146 Recruiting M.D. Anderson Cancer Center 2025-08-01
NCT03810196 CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT https://ClinicalTrials.gov/show/NCT03810196 Recruiting Children’s Hospital of Philadelphia 2024-01-31
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00719888 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease https://ClinicalTrials.gov/show/NCT00719888 Recruiting Fred Hutchinson Cancer Research Center 2022-12-31
NCT00669877 Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt’s and Burkitt’s -Like Leukemia/Lymphoma https://ClinicalTrials.gov/show/NCT00669877 Completed M.D. Anderson Cancer Center 2015-10-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00412243 Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients https://ClinicalTrials.gov/show/NCT00412243 Completed M.D. Anderson Cancer Center 2012-04-30
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00392990 Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt’s Lymphoma or Burkitt-Like Lymphoma https://ClinicalTrials.gov/show/NCT00392990 Completed Northwestern University 2011-12-03
NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt’s Lymphoma https://ClinicalTrials.gov/show/NCT00392834 Completed AIDS Malignancy Consortium 2011-07-31
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00388193 Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma https://ClinicalTrials.gov/show/NCT00388193 Completed PETHEMA Foundation 2013-12-31
NCT00363272 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00363272 Completed National Cancer Institute (NCI) 2008-10-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00303953 PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00303953 Completed National Cancer Institute (NCI) 2010-01-31
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00290472 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00290472 Completed National Cancer Institute (NCI) 2010-04-30
NCT00275080 Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00275080 Completed National Cancer Institute (NCI) 2009-11-30
NCT00217412 Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia https://ClinicalTrials.gov/show/NCT00217412 Completed National Cancer Institute (NCI) 2009-09-30
NCT00199082 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt’s Non-Hodgkin’s Lymphoma (NHL) and Other High-grade Lymphoma in Adults https://ClinicalTrials.gov/show/NCT00199082 Completed Johann Wolfgang Goethe University Hospital 2010-06-30
NCT00187161 Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL https://ClinicalTrials.gov/show/NCT00187161 Completed St. Jude Children’s Research Hospital NA
NCT00133991 Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt’s Lymphoma or Leukemia https://ClinicalTrials.gov/show/NCT00133991 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2011-08-31
NCT00119392 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00119392 Completed Fred Hutchinson Cancer Research Center 2009-07-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00118170 Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function https://ClinicalTrials.gov/show/NCT00118170 Completed National Cancer Institute (NCI) 2007-05-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00110071 Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00110071 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00109824 Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00109824 Completed National Cancer Institute (NCI) 2009-03-31
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00101270 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00101270 Completed National Cancer Institute (NCI) 2007-09-30
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00003166 Bryostatin and Vincristine in B-Cell Malignancies https://ClinicalTrials.gov/show/NCT00003166 Completed National Cancer Institute (NCI) 2001-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00073918 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00073918 Completed Fred Hutchinson Cancer Research Center 2011-10-02
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00064246 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder https://ClinicalTrials.gov/show/NCT00064246 Completed National Cancer Institute (NCI) 2004-09-30
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00060372 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer https://ClinicalTrials.gov/show/NCT00060372 Completed National Cancer Institute (NCI) 2008-04-30
NCT00058019 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00058019 Completed National Cancer Institute (NCI) 2010-08-31
NCT00057811 Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma https://ClinicalTrials.gov/show/NCT00057811 Completed Children’s Oncology Group 2009-10-31
NCT00054639 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00054639 Completed National Cancer Institute (NCI) 2010-01-31
NCT00054483 Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00054483 Completed National Cancer Institute (NCI) 2009-09-30
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00040690 Combination Chemotherapy in Treating Patients With Burkitt’s Lymphoma or Burkitt’s Leukemia https://ClinicalTrials.gov/show/NCT00040690 Completed National Cancer Institute (NCI) NA
NCT00039130 Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt’s Lymphoma or Burkitt’s Leukemia https://ClinicalTrials.gov/show/NCT00039130 Completed Alliance for Clinical Trials in Oncology 2010-09-30
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00016094 S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00016094 Completed National Cancer Institute (NCI) 2005-08-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00010192 Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00010192 Completed National Cancer Institute (NCI) 2003-01-31
NCT00006473 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00006473 Completed National Cancer Institute (NCI) 2006-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00002649 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00002649 Completed National Cancer Institute (NCI) 2006-11-30
NCT00001237 Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas https://ClinicalTrials.gov/show/NCT00001237 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001337 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00001337 Recruiting National Institutes of Health Clinical Center (CC) 2021-03-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT01809600 Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt’s or Burkitt-like Lymphoma in Adults https://ClinicalTrials.gov/show/NCT01809600 Completed Gachon University Gil Medical Center 2014-03-31
NCT01793233 Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas https://ClinicalTrials.gov/show/NCT01793233 Active, not recruiting Children’s Oncology Group 2020-12-31
NCT01623856 Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients https://ClinicalTrials.gov/show/NCT01623856 Completed Children’s Oncology Group 2012-06-30
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01196520 Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) https://ClinicalTrials.gov/show/NCT01196520 Completed National Institutes of Health Clinical Center (CC) 2015-12-31
NCT00949741 Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT00949741 Completed Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 2011-10-31
NCT00898755 Collecting and Storing Tissue From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898755 Completed Children’s Oncology Group 2008-07-17
NCT00822432 Coproporphyrine Isomers and Methotrexate Elimination https://ClinicalTrials.gov/show/NCT00822432 Completed Assistance Publique - Hôpitaux de Paris 2011-08-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03869619 REal World Data in LYmphoma and Survival in Adults https://ClinicalTrials.gov/show/NCT03869619 Recruiting Hospices Civils de Lyon 2027-10-31